The abnormal proliferation of cardiac fibroblasts is involved in the pathophysiologic process of left ventricular hypertrophy (LHV) associated with essential hypertension. Arginine vasopressin (AVP) has been reported to contribute significantly to the pathogenesis of hypertension. In this study, the authors investigated the effects of AVP and its V-1 receptor antagonist [d(CH2)(5)Tyr(2)(Me)]AVP on the growth of rat cardiac fibroblasts. Cardiac fibroblasts of neonatal Sprague-Dawley rats were isolated, and growth-arrested cardiac fibroblasts were stimulated with 2.5% fetal calf serum in the presence and absence of AVP (0.001, 0.01, 0.1, and 1 muM) and [d(CH2)(5)Tyr(2)(Me)]AVP (0.1 muM). DNA synthesis was measured by [H-3]thymidine incorporation. Thiazolyl blue assay and flow cytometry techniques were adopted to measure cell numbers and analyze cell cycle, respectively. Arginine vasopressin (0.1 and 1 muM) significantly increased DNA synthesis in cardiac fibroblasts. Moreover, AVP (0.1 and 1 muM) significantly increased the number of cardiac fibroblasts. Analysis of cell cycle showed that AVP (0.1 muM) increased S-stage percentage and proliferation index (PI). The V-1 receptor antagonist [d(CH2)(5)Tyr(2)(Me)]AVP (0.1 muM) significantly inhibited DNA synthesis in cardiac fibroblasts. The cell number, S-stage percentage, and PI induced by AVP (0.1 muM) were significantly decreased by [d(CH2)(5)Tyr(2)(Me)]AVP (0.1 muM). These findings suggest that AVP might promote the proliferation of rat cardiac fibroblasts, which seems to be mediated via the V-1 receptor. Arginine vasopressin may be involved in the pathopbysiologic process of LVH by promoting cardiac fibroblast proliferation.